clinical AI

A growing debate is unfolding over legal responsibility when artificial intelligence systems used in healthcare make errors. As AI tools move into diagnosis and treatment decisions, questions are mounting over whether doctors, hospitals, drugmakers or software developers should be held accountable when a wrong recommendation harms a patient, and regulators have yet to offer clear answers.

A viewpoint published by Chief Healthcare Executive argues that artificial intelligence is already transforming medical practice, and that medical education needs to change accordingly. The piece calls on educators to rethink how future doctors are trained so they can work alongside AI tools. It adds to a growing debate among healthcare leaders about whether curricula are keeping pace with rapid technological change in clinical settings.

A new report warns that a biomarker identified through artificial intelligence can appear accurate in its initial analysis yet still fail when put to its biggest test, typically validation in independent or clinical settings. The finding highlights a growing concern in medical research: AI-driven discoveries may reflect patterns in data rather than real, clinically useful signals, and researchers are being urged to apply stricter validation before trusting such results.

The Joint Commission, the main accreditor of US hospitals, is outlining how it views artificial intelligence in healthcare settings. The organization's perspective matters because its standards shape how hospitals adopt and govern AI tools, and healthcare leaders are watching for guidance on safety, oversight and accreditation expectations as AI use spreads across clinical operations.

Unauthorized AI agents are being flagged as an emerging risk in health care, raising concerns that autonomous tools could act within medical systems without proper oversight or approval. The discussion centers on how hospitals and regulators should control AI systems that handle sensitive patient data and clinical decisions before clear rules are in place.

CancerNetwork is examining how artificial intelligence is changing oncology, focusing on its effects on clinical trials, day-to-day workflows for oncologists, and patient outcomes. The discussion covers how AI tools may speed up trial design and patient matching, streamline administrative tasks in clinics, and ultimately influence treatment decisions. The broader question is whether these gains translate into measurably better results for people with cancer.

Utah is moving forward with additional pilot programs using artificial intelligence in health care, targeting prescription management and women's health services. The state has been among the more active in testing AI tools in clinical settings, and the new pilots signal continued government willingness to experiment with the technology despite ongoing national debate over safety, oversight, and patient data protections.

As artificial intelligence takes on a growing role in diagnosis, treatment planning and clinical workflows, medical training is being urged to keep pace. The argument is that doctors of the future will need new skills to work alongside AI tools, from interpreting algorithmic outputs to understanding their limitations, and that curricula must be updated now to prepare them.

Clinical software company CRScube has acquired Mednet, a provider of electronic data capture systems for clinical trials. The deal is aimed at expanding AI-assisted data entry capabilities across CRScube's clinical trial technology platform. The move signals continued consolidation in the clinical trial software sector as vendors race to integrate artificial intelligence into trial data management workflows.

Researchers have developed a deep learning tool that reads the regulatory code of leukemia cells to predict patient risk. By analyzing how genetic regulatory elements behave in cancer cells, the model aims to forecast how the disease will progress in individual patients. Such tools could help doctors tailor treatment intensity and identify high-risk cases earlier, though details on validation and clinical use remain limited.

Psychiatrist Christoph Correll discusses the use of artificial intelligence as a tool that can replace certain clinical tasks in psychiatric care. The conversation explores which routine responsibilities, such as documentation, monitoring, and triage, could be handed to AI systems, and what that shift means for clinicians and patients. Correll weighs the efficiency gains against concerns over clinical judgment, patient safety, and the human element of mental health treatment.

Insilico Medicine has nominated ISM1354, a GIPR antagonist designed using its artificial intelligence drug discovery platform, as a preclinical candidate for obesity and related metabolic diseases. The company says the molecule was generated and optimised end-to-end with generative AI tools. It adds to a growing slate of AI-discovered drugs moving toward clinical development, as pharmaceutical firms race to apply machine learning to the booming obesity treatment market.

A Los Angeles Times report says an AI startup is prescribing acne medication without a doctor directly reviewing each case, raising questions about patient safety and the limits of automated medicine. The story adds to a growing debate over how much clinical judgment can be delegated to AI systems in telehealth.

Sylvester Comprehensive Cancer Center is raising the question of who is helping determine how artificial intelligence is implemented in clinical trial operations. The item, highlighted by Oncodaily, points to an ongoing discussion in the oncology research community about the role clinicians, coordinators and sponsors play in adopting AI tools for running trials.

Clinical trial experts are adopting artificial intelligence and forming new partnerships as trials become more complex, according to industry reporting. The shift reflects mounting pressure on drug developers to design studies faster and manage increasingly complicated protocols, data volumes and patient recruitment challenges. The report highlights AI tools and collaboration as key strategies for streamlining clinical research operations.

Debate is growing over how much independence clinical AI agents should be given in patient care. The question centres on whether such systems should advise clinicians, act with human oversight, or make certain decisions on their own, touching on patient safety, accountability when errors occur, and regulatory standards for medical AI.

Physicians heading into 2026 are focused on three main issues: the rapid adoption of artificial intelligence in medicine, how pain is managed and understood, and the ongoing burnout crisis across the profession. The discussion reflects a medical community weighing the promise of new technology against the strain of workload and the everyday realities of patient care.

Behavioral health artificial intelligence is moving beyond one-off patient screening toward continuous monitoring of mental health risk, according to Memorial Care Innovation Fund. The shift suggests providers are exploring tools that track patients' wellbeing over time rather than relying on periodic assessments. Observers are watching how such systems could flag deterioration earlier, while questions remain about accuracy, privacy and clinical oversight.

The Reading Room Podcast has released the second part of its discussion on artificial intelligence in breast imaging, covering current perspectives, ongoing challenges, and future possibilities for the technology in breast cancer detection and diagnostics. The episode features expert commentary on how AI tools are being integrated into mammography and related imaging workflows, and what hurdles remain before broader clinical adoption.

The FDA has issued risk-based guidance on artificial intelligence, placing responsibility for validating AI tools squarely on sponsors rather than regulators. Companies developing drugs and clinical trials must now demonstrate their AI systems are reliable and appropriate for their intended use, with scrutiny scaling to the level of risk involved.

A heise online article on the use of AI in German rehabilitation clinics is drawing attention. It reports on discussions among doctors about how AI language models could relieve staff of documentation work, while raising open questions about the medical profession itself. Commenters argue the debate should not be limited to rehab clinics, since the same issues apply across the healthcare system.

New commentary in the pharmaceutical industry focuses on moving beyond AI experimentation toward practical adoption that accelerates the path from clinical and real-world evidence to action. The discussion highlights how drugmakers can embed AI into evidence generation, decision-making and operations, arguing that incremental, use-case-driven adoption delivers more value than large-scale speculative projects as the sector faces pressure to speed development.

Philips has published 12 statistics on the use of artificial intelligence in healthcare, drawn from its 2026 Future Health Index. The figures cover how hospitals and clinicians are adopting AI, and what the report suggests about the technology's growing role in patient care and health system planning.

A science news release outlines how artificial intelligence is being applied across therapeutic science, from predicting disease risk and classifying patient subgroups to guiding treatment decisions. The piece frames AI as a practical tool now shaping drug development and clinical care rather than a future concept. Specific studies, institutions and results behind the claims are not detailed, so the scope of the work remains unclear.

A new joint report by the European Academies Science Advisory Council (EASAC) and the Federation of European Academies of Medicine (FEAM) says artificial intelligence could help Europe deliver safer, higher-quality healthcare per clinician and per euro. The report warns this will only happen if AI tools are clinically validated, transparent, cybersecure and equitable, and it sets out ten policy actions for European policymakers to ensure safe adoption of AI in health systems.

The American Hospital Association is hosting a webinar examining how nurse-led artificial intelligence strategies can transform care delivery. The session will focus on how nurses can guide the adoption of AI tools in hospitals and health systems, reflecting growing interest in putting frontline clinicians at the centre of technology-driven change in patient care.

US federal researchers are expanding their use of artificial intelligence to speed up clinical trials, a process that traditionally takes years and high costs. The effort reflects a broader push in government health agencies to apply AI to drug development, patient recruitment, and trial design, with observers weighing the efficiency gains against concerns about data quality and regulatory oversight.

Rice University is holding its annual AI in Health Conference, bringing together experts to discuss how artificial intelligence is being applied in medicine and patient care. Sessions focus on innovation alongside ethical questions, including responsible use, patient privacy and fairness of AI tools in clinical settings, as health systems weigh rapid adoption of the technology.